Cholesterol Self-testing in Patients Post Acute Coronary Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Leipzig
About this trial
The pharmacological reduction of LDL-C lowers cardiovascular risk and is therefore a priority in cardiovascular secondary prevention. The achievement of LDL-C target levels in Germany, Europe, and worldwide is inadequate, despite a wide array of lipid-lowering medications. Only a small proportion of post-myocardial infarction patients reach their LDL-C target range within a year. There is a significant need for new strategies to improve LDL-C target achievement and thereby reduce the occurrence of secondary cardiovascular events.
The aim of the study is to establish a basis for improving prevention by achieving the target LDL level effectively and quickly in patients with high and very high cardiovascular risk profiles.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Patients with acute coronary syndrome in the last 6 months and not having reached the LDL target value
Signed informed consent
Disqualifiers
Persons unable to understand the study
Persons unable or unwilling to perform self-measurements
Persons unable or unwilling to undergo additional cholesterol-lowering therapy to reach the LDL target
Pre-menopausal women without contraception
Trial design
Treatments tested in this trial
- Cholesterol self-measurement
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov